Re: USA ZHCLF investors
in response to
by
posted on
Nov 02, 2022 12:01PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
All good point coldnewfie, anyone want give a gander ( Newfy term) why anyone would sell there ZHCLF shares at .15 cents, my guess , fed of of long timeline to exist from this investment. IMO just a few more years or less and assuming the trials have above 30% ORR and I think ZCC get money close to Constelaltion phrma or more $1.8 USD billion